Although this approach is potentially powerful for identifying IDH mutation status in high- and low-grade gliomas6,11,17–19, whether this method can be successfully applied for predicting pMGMT methylation status of GBM is still controversial. The gene discussed is IDH2; the disease is glioblastoma.